Sign Up
OverviewAPI
BioNTech and DualityBio have obtained FDA Fast Track designation for their BNT325/DB-1305, a next-generation antibody-drug conjugate targeting TROP2 for advanced ovarian cancers. The collaboration aims to address the unmet medical need in treating these cancers, with the potential for frequent engagement with the FDA to expedite the development and review process.

Ask a question